Pulmonx (LUNG) FDA Approvals

Pulmonx logo
$2.60 -0.20 (-7.25%)
As of 11:34 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Pulmonx's Drug in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by Pulmonx (LUNG). Over the past two years, Pulmonx has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as AeriSeal. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.

AeriSeal FDA Regulatory Events

AeriSeal is a drug developed by Pulmonx for the following indication: For bronchoscopic lung volume reduction (BLVR) and block collateral ventilation. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Pulmonx FDA Events - Frequently Asked Questions

As of now, Pulmonx (LUNG) has not received any FDA approvals for its therapy in the last two years.

In the past two years, Pulmonx (LUNG) has reported FDA regulatory activity for AeriSeal.

The most recent FDA-related event for Pulmonx occurred on November 17, 2026, involving AeriSeal. The update was categorized as "Publication," with the company reporting: "Pulmonx Corporation announced the online publication of results from the CONVERT Trial evaluating the AeriSeal® System in patients with severe emphysema and collateral ventilation, in Respiration: International Journal of Thoracic Medicine."

Currently, Pulmonx has one therapy (AeriSeal) targeting the following condition: For bronchoscopic lung volume reduction (BLVR) and block collateral ventilation..

  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

FDA progress for NASDAQ:LUNG last updated on 11/17/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
From Our Partners